ウルソデオキシコール酸の世界市場

ウルソデオキシコール酸の世界市場は2030年までに10億米ドルに達する見込み

2024年に5億7,210万米ドルと推定されるウルソデオキシコール酸の世界市場は、分析期間2024-2030年にCAGR 10.3%で成長し、2030年には10億米ドルに達すると予測されます。本レポートで分析したセグメントの1つである固形剤形は、CAGR 11.4%を記録し、分析期間終了時には7億6,770万米ドルに達すると予測されます。液体剤形セグメントの成長率は、分析期間中CAGR 7.4%と推定されます。

米国市場は1億5,590万米ドルと推定、中国はCAGR 14.2％で成長すると予測

米国のウルソデオキシコール酸市場は2024年に1億5,590万米ドルと推定されます。世界第2位の経済大国である中国は、分析期間2024-2030年のCAGRを14.2%として、2030年までに2億1,290万米ドルの市場規模に達すると予測されています。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ7.3%と9.1%と予測されています。欧州では、ドイツがCAGR約8.1%で成長すると予測されています。

世界のウルソデオキシコール酸市場- 主要動向と促進要因のまとめ

なぜウルソデオキシコール酸が現代の肝胆膵治療の中心なのか？

ウルソデオキシコール酸（UDCA）は、もともと熊の胆汁に含まれる二次胆汁酸で、現在では医薬品として合成されており、いくつかの慢性肝疾患や胆嚢関連疾患の治療の要となっています。特に、原発性胆汁性胆管炎（PBC）、手術非適応者の胆石溶解、妊娠性肝内胆汁うっ滞（ICP）などの管理において、極めて重要な役割を果たしています。アルコール摂取、メタボリックシンドローム、肝炎感染、自己免疫性肝疾患などに牽引され、肝疾患の世界の負担が増加の一途をたどるなか、UDCAのような効果的で非侵襲的な治療の必要性はこれまで以上に高まっています。胆汁の流れを改善し、胆汁酸毒性を軽減し、肝細胞を保護するUDCAは、多くの肝臓専門医にとって第一選択薬となっています。特に、新生児胆汁うっ滞や嚢胞性線維症に関連した肝合併症の治療など、小児科におけるUDCAの使用は拡大しています。世界人口の高齢化と肝疾患検診率の上昇に伴い、UDCAの臨床的意義は高まる一方です。非外科的性質、比較的良好な副作用プロファイル、免疫抑制を伴わずに疾患の進行を遅らせる能力により、UDCAは慢性肝疾患の治療において欠くことのできない資産となっています。

製剤とデリバリーにおける技術革新は、どのように有効性と患者のアドヒアランスを高めているのでしょうか？

様々な患者層におけるウルソデオキシコール酸の有用性と有効性を拡大する上で、製剤の革新が重要な役割を果たしています。従来のUDCA錠剤やカプセルは、小児患者や嚥下障害のある患者に対応するため、散剤、チュアブル剤、液剤に改良されています。また、徐放性製剤やマイクロカプセル製剤も登場し、胆汁酸濃度がより安定し、長期間のバイオアベイラビリティが向上するように設計されています。これと並行して、UDCAと他の胆汁酸調整剤や抗酸化剤との合剤も開発され、特に肝機能障害が進行した患者において治療効果を高めています。さらに、製薬メーカーは、患者がUDCA長期投与を中止する主な理由の一つである消化管耐容性を改善するため、賦形剤の最適化を進めています。このようなデリバリーシステムの改善は、コンプライアンスを向上させるだけでなく、PBCのような慢性的で進行の遅い疾患において重要な、薬物吸収のばらつきを減少させる。また、UDCAとFXRアゴニストやオベチコール酸のような次世代薬剤との併用による相乗効果の可能性を理解するための調査も進行中であり、肝保護療法の併用療法の新時代を切り開く可能性があります。

なぜ世界の動向はUDCA活用の新たな機会を生み出しているのか？

いくつかのマクロな健康動向は、UDCAの治療および商業的範囲を広げるために一致しています。第一に、非アルコール性脂肪性肝疾患（NAFLD）およびその重症型である非アルコール性脂肪性肝炎（NASH）の急増により、UDCAを含む胆汁酸モジュレーターの細胞保護作用および抗炎症作用に対する適応外の関心が高まっています。NASHに対するUDCAはまだ正式には承認されていないが、研究が続けられており、特定の症例に対する補助療法として処方されることもあります。第二に、血清学的検査と患者登録の改善により、まれな自己免疫性肝疾患に対する認識と診断が高まり、UDCAの対象となる患者層が拡大しています。産科領域では、双胎妊娠や体外受精歴のある患者を含む高リスク群における妊娠性肝内胆汁うっ滞のスクリーニングの強化により、周産期合併症を減らすための最前線の介入としてUDCA処方が増加しています。さらに、世界のファーマコビジランス基準の進化により、臨床医が有害な薬物相互作用をより効果的に特定・管理できるようになり、ポリファーマシーシーンにおいてもUDCAをより安全に長期使用できるようになっています。公衆衛生の優先事項が早期発見と予防的肝臓ケアにシフトする中、UDCAの役割は専門医とプライマリ・ケアの両方の経路で強化されつつあります。

ウルソデオキシコール酸市場の成長を促進する主な要因は？

ウルソデオキシコール酸市場の成長は、疾患の流行、医薬品の革新、世界のヘルスケアへのアクセスに関連するいくつかの要因によって牽引されています。PBC、胆汁うっ滞性肝障害、胆汁酸代謝異常などの慢性肝疾患の罹患率の増加が、成人および小児集団全体の需要を牽引しています。ドラッグデリバリー技術の進歩により、経口液剤や遅延放出錠剤など、多様な年齢層や合併症に対応した患者に優しい剤形が広く採用されるようになっています。ICPのような病態の管理におけるUDCAの適用範囲の拡大とNAFLD/NASH管理におけるUDCAの探求が、需要をさらに促進しています。欧州、北米、アジア太平洋における規制当局の承認や臨床ガイドラインの更新は、特に新しい胆汁酸療法が依然として高価であったり、利用しにくかったりすることから、より広範な使用を正当化しています。さらに、日常的な肝機能検査の増加と診断能力の向上により、より早期の治療開始が可能となり、生涯治療価値が高まっています。ジェネリック医薬品の増加やアジアにおける原薬製造の増加といった医薬品市場力学は、治療費を引き下げ、新興国における市場拡大を支えています。これらの要因が相まって、UDCA市場は堅調かつ上向きの成長軌道を描いています。

セグメント

剤形（固形剤、液体剤）;抽出様式（合成、生物学的）;用途（消化器疾患、肝疾患、嚢胞性線維症、その他の用途）;流通チャネル（病院薬局、小売薬局、オンライン薬局）

調査対象企業の例（注目の42社）

• ABC Farmaceutici SpA
• Adare Pharma Solutions
• ALP Pharm
• Anhui Biochem Pharmaceutical Co., Ltd.
• API Corporation
• Apicore
• Arch Pharmalabs Ltd.
• Asia Pioneer Pharmaceuticals
• Axplora
• Beijing Geyuantianrun Bio-tech Co., Ltd.
• Chengdu Chenlv Biological Technology Co., Ltd.
• Daewoong Pharmaceutical Co., Ltd.
• Dipharma Francis S.r.l.
• Erregierre S.p.A.
• Glenmark Pharmaceuticals Ltd.
• Grindeks
• Guangzhou Tosun Pharmaceutical Co., Ltd.
• Hanways Chempharm Co., Ltd.
• ICE Pharma
• Mankind Pharma Ltd.

関税影響係数

Global Industry Analystsは、本社国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、人為的な売上原価の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

Global Industry Analystsは、世界の主要なチーフ・エコノミスト（1万4,949人）、シンクタンク（62団体）、貿易・産業団体（171団体）の専門家の意見に熱心に従いながら、エコシステムへの影響を評価し、新たな市場の現実に対処しています。あらゆる主要国の専門家やエコノミストが、関税とそれが自国に与える影響についての意見を追跡調査しています。

Global Industry Analystsは、この混乱が今後2-3ヶ月で収束し、新しい世界秩序がより明確に確立されると予想しています。Global Industry Analystsは、これらの開発をリアルタイムで追跡しています。

2025年4月：交渉フェーズ

4月のリリースでは、世界市場全体に対する関税の影響を取り上げ、地域別の市場調整について紹介します。当社の予測は、過去のデータと進化する市場影響要因に基づいています。

2025年7月：最終関税リセット

無料アップデート弊社のお客様には、各国間で最終リセットが発表された後、7月に無料アップデート版をお届けします。最終アップデート版には、明確に定義された関税影響分析が組み込まれています。

相互および二国間貿易と関税の影響分析：

アメリカ <>中国<>メキシコ <>カナダ <>EU <>日本<>インド <>その他176カ国

業界をリードするエコノミスト：Global Industry Analystsの知識ベースは、国家、シンクタンク、貿易・産業団体、大企業、そして世界の計量経済状況におけるこの前例のないパラダイムシフトの影響を共有する領域の専門家など、最も影響力のあるチーフエコノミストの厳選されたグループを含む1万4,949人のエコノミストを追跡しています。当社の16,491を超えるレポートのほとんどは、マイルストーンに基づくこの2段階のリリーススケジュールを取り入れています。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

• 市場概要
• 主要企業
• 市場動向と促進要因
• 世界市場の見通し

第3章 市場分析

• 米国
• カナダ
• 日本
• 中国
• 欧州
• フランス
• ドイツ
• イタリア
• 英国
• スペイン
• ロシア
• その他欧州
• アジア太平洋
• オーストラリア
• インド
• 韓国
• その他アジア太平洋地域
• ラテンアメリカ
• アルゼンチン
• ブラジル
• メキシコ
• その他ラテンアメリカ
• 中東
• イラン
• イスラエル
• サウジアラビア
• アラブ首長国連邦
• その他中東
• アフリカ

第4章 競合

Global Ursodeoxycholic Acid Market to Reach US$1.0 Billion by 2030

The global market for Ursodeoxycholic Acid estimated at US$572.1 Million in the year 2024, is expected to reach US$1.0 Billion by 2030, growing at a CAGR of 10.3% over the analysis period 2024-2030. Solid Dosage Form, one of the segments analyzed in the report, is expected to record a 11.4% CAGR and reach US$767.7 Million by the end of the analysis period. Growth in the Liquid Dosage Form segment is estimated at 7.4% CAGR over the analysis period.

The U.S. Market is Estimated at US$155.9 Million While China is Forecast to Grow at 14.2% CAGR

The Ursodeoxycholic Acid market in the U.S. is estimated at US$155.9 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$212.9 Million by the year 2030 trailing a CAGR of 14.2% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 7.3% and 9.1% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 8.1% CAGR.

Global Ursodeoxycholic Acid Market - Key Trends & Drivers Summarized

Why Is Ursodeoxycholic Acid Central to Modern Hepatobiliary Therapies?

Ursodeoxycholic acid (UDCA), a secondary bile acid originally found in bear bile and now synthesized for pharmaceutical use, has become a cornerstone treatment for several chronic liver and gallbladder-related disorders. It plays a pivotal role in managing primary biliary cholangitis (PBC), gallstone dissolution in non-candidates for surgery, and intrahepatic cholestasis of pregnancy (ICP), among other conditions. As the global burden of liver diseases continues to rise-driven by alcohol consumption, metabolic syndrome, hepatitis infections, and autoimmune liver diseases-the need for effective, non-invasive treatments like UDCA is more urgent than ever. Its ability to improve bile flow, reduce bile acid toxicity, and protect hepatocytes makes it a first-line option for many hepatologists. Notably, UDCA’s use in pediatrics is expanding, especially in treating neonatal cholestasis and cystic fibrosis-related liver complications. With an aging global population and increasing liver disease screening rates, the clinical relevance of UDCA is only intensifying. Its non-surgical nature, relatively favorable side effect profile, and ability to delay disease progression without immunosuppression make it an indispensable asset in chronic liver care.

How Are Innovations in Formulations and Delivery Enhancing Efficacy and Patient Adherence?

Formulation innovation is playing a crucial role in expanding the usability and effectiveness of ursodeoxycholic acid across varied patient demographics. Traditional UDCA tablets and capsules are being reformulated into dispersible, chewable, and liquid forms to cater to pediatric patients and those with dysphagia. Sustained-release and microencapsulated delivery formats are also emerging, designed to offer more stable bile acid levels and better bioavailability over longer durations. In parallel, fixed-dose combinations of UDCA with other bile acid modulators or antioxidants are being developed to enhance therapeutic impact, particularly in patients with advanced liver dysfunction. Additionally, pharmaceutical manufacturers are optimizing excipients to improve gastrointestinal tolerance, one of the main reasons patients discontinue long-term UDCA therapy. These improvements in delivery systems are not only enhancing compliance but also reducing variability in drug absorption, which is critical in chronic, slow-progressing diseases like PBC. Research is also underway to understand the potential synergistic effects of combining UDCA with next-generation agents like FXR agonists or obeticholic acid, potentially ushering in a new era of combination hepatoprotective therapies.

Why Are Global Health Trends Creating New Opportunities for UDCA Utilization?

Several macro health trends are aligning to widen the therapeutic and commercial scope of UDCA. First, the surge in non-alcoholic fatty liver disease (NAFLD) and its more severe form, non-alcoholic steatohepatitis (NASH), is prompting off-label interest in bile acid modulators, including UDCA, for their cytoprotective and anti-inflammatory properties. Although not yet formally approved for NASH, UDCA continues to be studied and sometimes prescribed as adjunct therapy in specific cases. Secondly, rising awareness and diagnosis of rare autoimmune liver diseases-facilitated by improved serological testing and patient registries-are expanding the eligible patient pool for UDCA. In obstetrics, greater screening for intrahepatic cholestasis of pregnancy in high-risk groups, including those with twin pregnancies or IVF histories, is increasing UDCA prescriptions as a frontline intervention to reduce perinatal complications. Furthermore, evolving global pharmacovigilance standards are helping clinicians identify and manage adverse drug interactions more effectively, ensuring safer long-term use of UDCA even in polypharmacy scenarios. As public health priorities shift toward early detection and preventive liver care, UDCA’s role is being reinforced in both specialist and primary care pathways.

What Are the Key Factors Driving Growth in the Ursodeoxycholic Acid Market?

The growth in the ursodeoxycholic acid market is driven by several factors tied to disease prevalence, pharmaceutical innovation, and global healthcare accessibility. Increasing incidence of chronic liver diseases-including PBC, cholestatic liver disorders, and bile acid metabolism abnormalities-is driving demand across both adult and pediatric populations. Advances in drug formulation technologies are enabling wider adoption through patient-friendly delivery formats such as oral liquids and delayed-release tablets, which cater to diverse age groups and comorbidities. The expanding scope of UDCA in managing conditions like ICP and its exploration in NAFLD/NASH management are further propelling demand. Regulatory approvals and updated clinical guidelines in Europe, North America, and Asia-Pacific are legitimizing wider use, especially as newer bile acid therapies remain costlier or less accessible. Additionally, the rise in routine liver function testing and better diagnostic capabilities are allowing earlier initiation of therapy, increasing lifetime treatment value. Pharmaceutical market dynamics, such as the growth of generics and increased API manufacturing in Asia, are lowering treatment costs and supporting market expansion in emerging economies. Collectively, these factors are shaping a robust and upward growth trajectory for the UDCA market.

SCOPE OF STUDY:

The report analyzes the Ursodeoxycholic Acid market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Dosage Form (Solid Dosage Form, Liquid Dosage Form); Mode of Extraction (Synthetic, Biological); Application (Gastrointestinal Disorders, Liver Disorders, Cystic Fibrosis, Other Applications); Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 42 Featured) -

• ABC Farmaceutici SpA
• Adare Pharma Solutions
• ALP Pharm
• Anhui Biochem Pharmaceutical Co., Ltd.
• API Corporation
• Apicore
• Arch Pharmalabs Ltd.
• Asia Pioneer Pharmaceuticals
• Axplora
• Beijing Geyuantianrun Bio-tech Co., Ltd.
• Chengdu Chenlv Biological Technology Co., Ltd.
• Daewoong Pharmaceutical Co., Ltd.
• Dipharma Francis S.r.l.
• Erregierre S.p.A.
• Glenmark Pharmaceuticals Ltd.
• Grindeks
• Guangzhou Tosun Pharmaceutical Co., Ltd.
• Hanways Chempharm Co., Ltd.
• ICE Pharma
• Mankind Pharma Ltd.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA <> CHINA <> MEXICO <> CANADA <> EU <> JAPAN <> INDIA <> 176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

COMPLIMENTARY PREVIEW

Contact your sales agent to request an online 300+ page complimentary preview of this research project. Our preview will present full stack sources, and validated domain expert data transcripts. Deep dive into our interactive data-driven online platform.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Impact of Covid-19 and a Looming Global Recession
  • Ursodeoxycholic Acid - Global Key Competitors Percentage Market Share in 2025 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Rising Incidence of Cholestatic Liver Diseases Drives Long-Term Demand
  • Increasing Focus on Rare Liver Conditions Expands Addressable Patient Pool
  • Development of Pediatric Formulations Strengthens Therapeutic Reach
  • Global Surge in Obesity and Associated Liver Disorders Spurs Growth
  • Inclusion in Essential Medicines List Propels Adoption in Developing Markets
  • Expanding Use in Gallstone Prevention Generates Demand in At-Risk Populations
  • Growing Awareness Among Physicians Enhances Prescription Rates
  • Patent Expiries Create Opportunities for Generic Market Penetration
  • Cross-Border Licensing Deals Accelerate International Availability
  • Regulatory Approvals for New Indications Throw the Spotlight on Expanded Use
  • Advancements in Drug Delivery Formulations Sustain Patient Compliance
  • Investment in Hepatology Research Strengthens Business Case for Continued Use
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Ursodeoxycholic Acid Market Analysis of Annual Sales in US$ Thousand for Years 2015 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for Ursodeoxycholic Acid by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 3: World Historic Review for Ursodeoxycholic Acid by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 4: World 15-Year Perspective for Ursodeoxycholic Acid by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
  • TABLE 5: World Recent Past, Current & Future Analysis for Solid Dosage Form by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 6: World Historic Review for Solid Dosage Form by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 7: World 15-Year Perspective for Solid Dosage Form by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for Liquid Dosage Form by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 9: World Historic Review for Liquid Dosage Form by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 10: World 15-Year Perspective for Liquid Dosage Form by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 11: World Recent Past, Current & Future Analysis for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 12: World Historic Review for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 13: World 15-Year Perspective for Retail Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 14: World Recent Past, Current & Future Analysis for Online Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 15: World Historic Review for Online Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 16: World 15-Year Perspective for Online Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 17: World Recent Past, Current & Future Analysis for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 18: World Historic Review for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 19: World 15-Year Perspective for Hospital Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 20: World Recent Past, Current & Future Analysis for Synthetic by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 21: World Historic Review for Synthetic by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 22: World 15-Year Perspective for Synthetic by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 23: World Recent Past, Current & Future Analysis for Biological by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 24: World Historic Review for Biological by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 25: World 15-Year Perspective for Biological by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 26: World Recent Past, Current & Future Analysis for Gastrointestinal Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 27: World Historic Review for Gastrointestinal Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 28: World 15-Year Perspective for Gastrointestinal Disorders by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 29: World Recent Past, Current & Future Analysis for Liver Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 30: World Historic Review for Liver Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 31: World 15-Year Perspective for Liver Disorders by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 32: World Recent Past, Current & Future Analysis for Cystic Fibrosis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 33: World Historic Review for Cystic Fibrosis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 34: World 15-Year Perspective for Cystic Fibrosis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 35: World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 36: World Historic Review for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 37: World 15-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Ursodeoxycholic Acid Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
  • TABLE 38: USA Recent Past, Current & Future Analysis for Ursodeoxycholic Acid by Dosage Form - Solid Dosage Form and Liquid Dosage Form - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 39: USA Historic Review for Ursodeoxycholic Acid by Dosage Form - Solid Dosage Form and Liquid Dosage Form Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 40: USA 15-Year Perspective for Ursodeoxycholic Acid by Dosage Form - Percentage Breakdown of Value Sales for Solid Dosage Form and Liquid Dosage Form for the Years 2015, 2025 & 2030
  • TABLE 41: USA Recent Past, Current & Future Analysis for Ursodeoxycholic Acid by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 42: USA Historic Review for Ursodeoxycholic Acid by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 43: USA 15-Year Perspective for Ursodeoxycholic Acid by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 44: USA Recent Past, Current & Future Analysis for Ursodeoxycholic Acid by Mode of Extraction - Synthetic and Biological - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 45: USA Historic Review for Ursodeoxycholic Acid by Mode of Extraction - Synthetic and Biological Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 46: USA 15-Year Perspective for Ursodeoxycholic Acid by Mode of Extraction - Percentage Breakdown of Value Sales for Synthetic and Biological for the Years 2015, 2025 & 2030
  • TABLE 47: USA Recent Past, Current & Future Analysis for Ursodeoxycholic Acid by Application - Gastrointestinal Disorders, Liver Disorders, Cystic Fibrosis and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 48: USA Historic Review for Ursodeoxycholic Acid by Application - Gastrointestinal Disorders, Liver Disorders, Cystic Fibrosis and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 49: USA 15-Year Perspective for Ursodeoxycholic Acid by Application - Percentage Breakdown of Value Sales for Gastrointestinal Disorders, Liver Disorders, Cystic Fibrosis and Other Applications for the Years 2015, 2025 & 2030
• CANADA
  • TABLE 50: Canada Recent Past, Current & Future Analysis for Ursodeoxycholic Acid by Dosage Form - Solid Dosage Form and Liquid Dosage Form - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 51: Canada Historic Review for Ursodeoxycholic Acid by Dosage Form - Solid Dosage Form and Liquid Dosage Form Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 52: Canada 15-Year Perspective for Ursodeoxycholic Acid by Dosage Form - Percentage Breakdown of Value Sales for Solid Dosage Form and Liquid Dosage Form for the Years 2015, 2025 & 2030
  • TABLE 53: Canada Recent Past, Current & Future Analysis for Ursodeoxycholic Acid by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 54: Canada Historic Review for Ursodeoxycholic Acid by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 55: Canada 15-Year Perspective for Ursodeoxycholic Acid by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 56: Canada Recent Past, Current & Future Analysis for Ursodeoxycholic Acid by Mode of Extraction - Synthetic and Biological - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 57: Canada Historic Review for Ursodeoxycholic Acid by Mode of Extraction - Synthetic and Biological Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 58: Canada 15-Year Perspective for Ursodeoxycholic Acid by Mode of Extraction - Percentage Breakdown of Value Sales for Synthetic and Biological for the Years 2015, 2025 & 2030
  • TABLE 59: Canada Recent Past, Current & Future Analysis for Ursodeoxycholic Acid by Application - Gastrointestinal Disorders, Liver Disorders, Cystic Fibrosis and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 60: Canada Historic Review for Ursodeoxycholic Acid by Application - Gastrointestinal Disorders, Liver Disorders, Cystic Fibrosis and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 61: Canada 15-Year Perspective for Ursodeoxycholic Acid by Application - Percentage Breakdown of Value Sales for Gastrointestinal Disorders, Liver Disorders, Cystic Fibrosis and Other Applications for the Years 2015, 2025 & 2030
• JAPAN
  • Ursodeoxycholic Acid Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
  • TABLE 62: Japan Recent Past, Current & Future Analysis for Ursodeoxycholic Acid by Dosage Form - Solid Dosage Form and Liquid Dosage Form - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 63: Japan Historic Review for Ursodeoxycholic Acid by Dosage Form - Solid Dosage Form and Liquid Dosage Form Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 64: Japan 15-Year Perspective for Ursodeoxycholic Acid by Dosage Form - Percentage Breakdown of Value Sales for Solid Dosage Form and Liquid Dosage Form for the Years 2015, 2025 & 2030
  • TABLE 65: Japan Recent Past, Current & Future Analysis for Ursodeoxycholic Acid by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 66: Japan Historic Review for Ursodeoxycholic Acid by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 67: Japan 15-Year Perspective for Ursodeoxycholic Acid by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 68: Japan Recent Past, Current & Future Analysis for Ursodeoxycholic Acid by Mode of Extraction - Synthetic and Biological - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 69: Japan Historic Review for Ursodeoxycholic Acid by Mode of Extraction - Synthetic and Biological Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 70: Japan 15-Year Perspective for Ursodeoxycholic Acid by Mode of Extraction - Percentage Breakdown of Value Sales for Synthetic and Biological for the Years 2015, 2025 & 2030
  • TABLE 71: Japan Recent Past, Current & Future Analysis for Ursodeoxycholic Acid by Application - Gastrointestinal Disorders, Liver Disorders, Cystic Fibrosis and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 72: Japan Historic Review for Ursodeoxycholic Acid by Application - Gastrointestinal Disorders, Liver Disorders, Cystic Fibrosis and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 73: Japan 15-Year Perspective for Ursodeoxycholic Acid by Application - Percentage Breakdown of Value Sales for Gastrointestinal Disorders, Liver Disorders, Cystic Fibrosis and Other Applications for the Years 2015, 2025 & 2030
• CHINA
  • Ursodeoxycholic Acid Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
  • TABLE 74: China Recent Past, Current & Future Analysis for Ursodeoxycholic Acid by Dosage Form - Solid Dosage Form and Liquid Dosage Form - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 75: China Historic Review for Ursodeoxycholic Acid by Dosage Form - Solid Dosage Form and Liquid Dosage Form Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 76: China 15-Year Perspective for Ursodeoxycholic Acid by Dosage Form - Percentage Breakdown of Value Sales for Solid Dosage Form and Liquid Dosage Form for the Years 2015, 2025 & 2030
  • TABLE 77: China Recent Past, Current & Future Analysis for Ursodeoxycholic Acid by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 78: China Historic Review for Ursodeoxycholic Acid by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 79: China 15-Year Perspective for Ursodeoxycholic Acid by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 80: China Recent Past, Current & Future Analysis for Ursodeoxycholic Acid by Mode of Extraction - Synthetic and Biological - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 81: China Historic Review for Ursodeoxycholic Acid by Mode of Extraction - Synthetic and Biological Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 82: China 15-Year Perspective for Ursodeoxycholic Acid by Mode of Extraction - Percentage Breakdown of Value Sales for Synthetic and Biological for the Years 2015, 2025 & 2030
  • TABLE 83: China Recent Past, Current & Future Analysis for Ursodeoxycholic Acid by Application - Gastrointestinal Disorders, Liver Disorders, Cystic Fibrosis and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 84: China Historic Review for Ursodeoxycholic Acid by Application - Gastrointestinal Disorders, Liver Disorders, Cystic Fibrosis and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 85: China 15-Year Perspective for Ursodeoxycholic Acid by Application - Percentage Breakdown of Value Sales for Gastrointestinal Disorders, Liver Disorders, Cystic Fibrosis and Other Applications for the Years 2015, 2025 & 2030
• EUROPE
  • Ursodeoxycholic Acid Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
  • TABLE 86: Europe Recent Past, Current & Future Analysis for Ursodeoxycholic Acid by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 87: Europe Historic Review for Ursodeoxycholic Acid by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 88: Europe 15-Year Perspective for Ursodeoxycholic Acid by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
  • TABLE 89: Europe Recent Past, Current & Future Analysis for Ursodeoxycholic Acid by Dosage Form - Solid Dosage Form and Liquid Dosage Form - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 90: Europe Historic Review for Ursodeoxycholic Acid by Dosage Form - Solid Dosage Form and Liquid Dosage Form Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 91: Europe 15-Year Perspective for Ursodeoxycholic Acid by Dosage Form - Percentage Breakdown of Value Sales for Solid Dosage Form and Liquid Dosage Form for the Years 2015, 2025 & 2030
  • TABLE 92: Europe Recent Past, Current & Future Analysis for Ursodeoxycholic Acid by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 93: Europe Historic Review for Ursodeoxycholic Acid by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 94: Europe 15-Year Perspective for Ursodeoxycholic Acid by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 95: Europe Recent Past, Current & Future Analysis for Ursodeoxycholic Acid by Mode of Extraction - Synthetic and Biological - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 96: Europe Historic Review for Ursodeoxycholic Acid by Mode of Extraction - Synthetic and Biological Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 97: Europe 15-Year Perspective for Ursodeoxycholic Acid by Mode of Extraction - Percentage Breakdown of Value Sales for Synthetic and Biological for the Years 2015, 2025 & 2030
  • TABLE 98: Europe Recent Past, Current & Future Analysis for Ursodeoxycholic Acid by Application - Gastrointestinal Disorders, Liver Disorders, Cystic Fibrosis and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 99: Europe Historic Review for Ursodeoxycholic Acid by Application - Gastrointestinal Disorders, Liver Disorders, Cystic Fibrosis and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 100: Europe 15-Year Perspective for Ursodeoxycholic Acid by Application - Percentage Breakdown of Value Sales for Gastrointestinal Disorders, Liver Disorders, Cystic Fibrosis and Other Applications for the Years 2015, 2025 & 2030
• FRANCE
  • Ursodeoxycholic Acid Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
  • TABLE 101: France Recent Past, Current & Future Analysis for Ursodeoxycholic Acid by Dosage Form - Solid Dosage Form and Liquid Dosage Form - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 102: France Historic Review for Ursodeoxycholic Acid by Dosage Form - Solid Dosage Form and Liquid Dosage Form Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 103: France 15-Year Perspective for Ursodeoxycholic Acid by Dosage Form - Percentage Breakdown of Value Sales for Solid Dosage Form and Liquid Dosage Form for the Years 2015, 2025 & 2030
  • TABLE 104: France Recent Past, Current & Future Analysis for Ursodeoxycholic Acid by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 105: France Historic Review for Ursodeoxycholic Acid by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 106: France 15-Year Perspective for Ursodeoxycholic Acid by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 107: France Recent Past, Current & Future Analysis for Ursodeoxycholic Acid by Mode of Extraction - Synthetic and Biological - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 108: France Historic Review for Ursodeoxycholic Acid by Mode of Extraction - Synthetic and Biological Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 109: France 15-Year Perspective for Ursodeoxycholic Acid by Mode of Extraction - Percentage Breakdown of Value Sales for Synthetic and Biological for the Years 2015, 2025 & 2030
  • TABLE 110: France Recent Past, Current & Future Analysis for Ursodeoxycholic Acid by Application - Gastrointestinal Disorders, Liver Disorders, Cystic Fibrosis and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 111: France Historic Review for Ursodeoxycholic Acid by Application - Gastrointestinal Disorders, Liver Disorders, Cystic Fibrosis and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 112: France 15-Year Perspective for Ursodeoxycholic Acid by Application - Percentage Breakdown of Value Sales for Gastrointestinal Disorders, Liver Disorders, Cystic Fibrosis and Other Applications for the Years 2015, 2025 & 2030
• GERMANY
  • Ursodeoxycholic Acid Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
  • TABLE 113: Germany Recent Past, Current & Future Analysis for Ursodeoxycholic Acid by Dosage Form - Solid Dosage Form and Liquid Dosage Form - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 114: Germany Historic Review for Ursodeoxycholic Acid by Dosage Form - Solid Dosage Form and Liquid Dosage Form Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 115: Germany 15-Year Perspective for Ursodeoxycholic Acid by Dosage Form - Percentage Breakdown of Value Sales for Solid Dosage Form and Liquid Dosage Form for the Years 2015, 2025 & 2030
  • TABLE 116: Germany Recent Past, Current & Future Analysis for Ursodeoxycholic Acid by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 117: Germany Historic Review for Ursodeoxycholic Acid by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 118: Germany 15-Year Perspective for Ursodeoxycholic Acid by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 119: Germany Recent Past, Current & Future Analysis for Ursodeoxycholic Acid by Mode of Extraction - Synthetic and Biological - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 120: Germany Historic Review for Ursodeoxycholic Acid by Mode of Extraction - Synthetic and Biological Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 121: Germany 15-Year Perspective for Ursodeoxycholic Acid by Mode of Extraction - Percentage Breakdown of Value Sales for Synthetic and Biological for the Years 2015, 2025 & 2030
  • TABLE 122: Germany Recent Past, Current & Future Analysis for Ursodeoxycholic Acid by Application - Gastrointestinal Disorders, Liver Disorders, Cystic Fibrosis and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 123: Germany Historic Review for Ursodeoxycholic Acid by Application - Gastrointestinal Disorders, Liver Disorders, Cystic Fibrosis and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 124: Germany 15-Year Perspective for Ursodeoxycholic Acid by Application - Percentage Breakdown of Value Sales for Gastrointestinal Disorders, Liver Disorders, Cystic Fibrosis and Other Applications for the Years 2015, 2025 & 2030
• ITALY
  • TABLE 125: Italy Recent Past, Current & Future Analysis for Ursodeoxycholic Acid by Dosage Form - Solid Dosage Form and Liquid Dosage Form - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 126: Italy Historic Review for Ursodeoxycholic Acid by Dosage Form - Solid Dosage Form and Liquid Dosage Form Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 127: Italy 15-Year Perspective for Ursodeoxycholic Acid by Dosage Form - Percentage Breakdown of Value Sales for Solid Dosage Form and Liquid Dosage Form for the Years 2015, 2025 & 2030
  • TABLE 128: Italy Recent Past, Current & Future Analysis for Ursodeoxycholic Acid by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 129: Italy Historic Review for Ursodeoxycholic Acid by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 130: Italy 15-Year Perspective for Ursodeoxycholic Acid by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 131: Italy Recent Past, Current & Future Analysis for Ursodeoxycholic Acid by Mode of Extraction - Synthetic and Biological - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 132: Italy Historic Review for Ursodeoxycholic Acid by Mode of Extraction - Synthetic and Biological Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 133: Italy 15-Year Perspective for Ursodeoxycholic Acid by Mode of Extraction - Percentage Breakdown of Value Sales for Synthetic and Biological for the Years 2015, 2025 & 2030
  • TABLE 134: Italy Recent Past, Current & Future Analysis for Ursodeoxycholic Acid by Application - Gastrointestinal Disorders, Liver Disorders, Cystic Fibrosis and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 135: Italy Historic Review for Ursodeoxycholic Acid by Application - Gastrointestinal Disorders, Liver Disorders, Cystic Fibrosis and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 136: Italy 15-Year Perspective for Ursodeoxycholic Acid by Application - Percentage Breakdown of Value Sales for Gastrointestinal Disorders, Liver Disorders, Cystic Fibrosis and Other Applications for the Years 2015, 2025 & 2030
• UNITED KINGDOM
  • Ursodeoxycholic Acid Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
  • TABLE 137: UK Recent Past, Current & Future Analysis for Ursodeoxycholic Acid by Dosage Form - Solid Dosage Form and Liquid Dosage Form - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 138: UK Historic Review for Ursodeoxycholic Acid by Dosage Form - Solid Dosage Form and Liquid Dosage Form Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 139: UK 15-Year Perspective for Ursodeoxycholic Acid by Dosage Form - Percentage Breakdown of Value Sales for Solid Dosage Form and Liquid Dosage Form for the Years 2015, 2025 & 2030
  • TABLE 140: UK Recent Past, Current & Future Analysis for Ursodeoxycholic Acid by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 141: UK Historic Review for Ursodeoxycholic Acid by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 142: UK 15-Year Perspective for Ursodeoxycholic Acid by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 143: UK Recent Past, Current & Future Analysis for Ursodeoxycholic Acid by Mode of Extraction - Synthetic and Biological - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 144: UK Historic Review for Ursodeoxycholic Acid by Mode of Extraction - Synthetic and Biological Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 145: UK 15-Year Perspective for Ursodeoxycholic Acid by Mode of Extraction - Percentage Breakdown of Value Sales for Synthetic and Biological for the Years 2015, 2025 & 2030
  • TABLE 146: UK Recent Past, Current & Future Analysis for Ursodeoxycholic Acid by Application - Gastrointestinal Disorders, Liver Disorders, Cystic Fibrosis and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 147: UK Historic Review for Ursodeoxycholic Acid by Application - Gastrointestinal Disorders, Liver Disorders, Cystic Fibrosis and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 148: UK 15-Year Perspective for Ursodeoxycholic Acid by Application - Percentage Breakdown of Value Sales for Gastrointestinal Disorders, Liver Disorders, Cystic Fibrosis and Other Applications for the Years 2015, 2025 & 2030
• SPAIN
  • TABLE 149: Spain Recent Past, Current & Future Analysis for Ursodeoxycholic Acid by Dosage Form - Solid Dosage Form and Liquid Dosage Form - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 150: Spain Historic Review for Ursodeoxycholic Acid by Dosage Form - Solid Dosage Form and Liquid Dosage Form Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 151: Spain 15-Year Perspective for Ursodeoxycholic Acid by Dosage Form - Percentage Breakdown of Value Sales for Solid Dosage Form and Liquid Dosage Form for the Years 2015, 2025 & 2030
  • TABLE 152: Spain Recent Past, Current & Future Analysis for Ursodeoxycholic Acid by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 153: Spain Historic Review for Ursodeoxycholic Acid by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 154: Spain 15-Year Perspective for Ursodeoxycholic Acid by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 155: Spain Recent Past, Current & Future Analysis for Ursodeoxycholic Acid by Mode of Extraction - Synthetic and Biological - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 156: Spain Historic Review for Ursodeoxycholic Acid by Mode of Extraction - Synthetic and Biological Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 157: Spain 15-Year Perspective for Ursodeoxycholic Acid by Mode of Extraction - Percentage Breakdown of Value Sales for Synthetic and Biological for the Years 2015, 2025 & 2030
  • TABLE 158: Spain Recent Past, Current & Future Analysis for Ursodeoxycholic Acid by Application - Gastrointestinal Disorders, Liver Disorders, Cystic Fibrosis and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 159: Spain Historic Review for Ursodeoxycholic Acid by Application - Gastrointestinal Disorders, Liver Disorders, Cystic Fibrosis and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 160: Spain 15-Year Perspective for Ursodeoxycholic Acid by Application - Percentage Breakdown of Value Sales for Gastrointestinal Disorders, Liver Disorders, Cystic Fibrosis and Other Applications for the Years 2015, 2025 & 2030
• RUSSIA
  • TABLE 161: Russia Recent Past, Current & Future Analysis for Ursodeoxycholic Acid by Dosage Form - Solid Dosage Form and Liquid Dosage Form - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 162: Russia Historic Review for Ursodeoxycholic Acid by Dosage Form - Solid Dosage Form and Liquid Dosage Form Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 163: Russia 15-Year Perspective for Ursodeoxycholic Acid by Dosage Form - Percentage Breakdown of Value Sales for Solid Dosage Form and Liquid Dosage Form for the Years 2015, 2025 & 2030
  • TABLE 164: Russia Recent Past, Current & Future Analysis for Ursodeoxycholic Acid by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 165: Russia Historic Review for Ursodeoxycholic Acid by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 166: Russia 15-Year Perspective for Ursodeoxycholic Acid by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 167: Russia Recent Past, Current & Future Analysis for Ursodeoxycholic Acid by Mode of Extraction - Synthetic and Biological - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 168: Russia Historic Review for Ursodeoxycholic Acid by Mode of Extraction - Synthetic and Biological Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 169: Russia 15-Year Perspective for Ursodeoxycholic Acid by Mode of Extraction - Percentage Breakdown of Value Sales for Synthetic and Biological for the Years 2015, 2025 & 2030
  • TABLE 170: Russia Recent Past, Current & Future Analysis for Ursodeoxycholic Acid by Application - Gastrointestinal Disorders, Liver Disorders, Cystic Fibrosis and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 171: Russia Historic Review for Ursodeoxycholic Acid by Application - Gastrointestinal Disorders, Liver Disorders, Cystic Fibrosis and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 172: Russia 15-Year Perspective for Ursodeoxycholic Acid by Application - Percentage Breakdown of Value Sales for Gastrointestinal Disorders, Liver Disorders, Cystic Fibrosis and Other Applications for the Years 2015, 2025 & 2030
• REST OF EUROPE
  • TABLE 173: Rest of Europe Recent Past, Current & Future Analysis for Ursodeoxycholic Acid by Dosage Form - Solid Dosage Form and Liquid Dosage Form - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 174: Rest of Europe Historic Review for Ursodeoxycholic Acid by Dosage Form - Solid Dosage Form and Liquid Dosage Form Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 175: Rest of Europe 15-Year Perspective for Ursodeoxycholic Acid by Dosage Form - Percentage Breakdown of Value Sales for Solid Dosage Form and Liquid Dosage Form for the Years 2015, 2025 & 2030
  • TABLE 176: Rest of Europe Recent Past, Current & Future Analysis for Ursodeoxycholic Acid by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 177: Rest of Europe Historic Review for Ursodeoxycholic Acid by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 178: Rest of Europe 15-Year Perspective for Ursodeoxycholic Acid by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 179: Rest of Europe Recent Past, Current & Future Analysis for Ursodeoxycholic Acid by Mode of Extraction - Synthetic and Biological - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 180: Rest of Europe Historic Review for Ursodeoxycholic Acid by Mode of Extraction - Synthetic and Biological Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 181: Rest of Europe 15-Year Perspective for Ursodeoxycholic Acid by Mode of Extraction - Percentage Breakdown of Value Sales for Synthetic and Biological for the Years 2015, 2025 & 2030
  • TABLE 182: Rest of Europe Recent Past, Current & Future Analysis for Ursodeoxycholic Acid by Application - Gastrointestinal Disorders, Liver Disorders, Cystic Fibrosis and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 183: Rest of Europe Historic Review for Ursodeoxycholic Acid by Application - Gastrointestinal Disorders, Liver Disorders, Cystic Fibrosis and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 184: Rest of Europe 15-Year Perspective for Ursodeoxycholic Acid by Application - Percentage Breakdown of Value Sales for Gastrointestinal Disorders, Liver Disorders, Cystic Fibrosis and Other Applications for the Years 2015, 2025 & 2030
• ASIA-PACIFIC
  • Ursodeoxycholic Acid Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
  • TABLE 185: Asia-Pacific Recent Past, Current & Future Analysis for Ursodeoxycholic Acid by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 186: Asia-Pacific Historic Review for Ursodeoxycholic Acid by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 187: Asia-Pacific 15-Year Perspective for Ursodeoxycholic Acid by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
  • TABLE 188: Asia-Pacific Recent Past, Current & Future Analysis for Ursodeoxycholic Acid by Dosage Form - Solid Dosage Form and Liquid Dosage Form - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 189: Asia-Pacific Historic Review for Ursodeoxycholic Acid by Dosage Form - Solid Dosage Form and Liquid Dosage Form Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 190: Asia-Pacific 15-Year Perspective for Ursodeoxycholic Acid by Dosage Form - Percentage Breakdown of Value Sales for Solid Dosage Form and Liquid Dosage Form for the Years 2015, 2025 & 2030
  • TABLE 191: Asia-Pacific Recent Past, Current & Future Analysis for Ursodeoxycholic Acid by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 192: Asia-Pacific Historic Review for Ursodeoxycholic Acid by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 193: Asia-Pacific 15-Year Perspective for Ursodeoxycholic Acid by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 194: Asia-Pacific Recent Past, Current & Future Analysis for Ursodeoxycholic Acid by Mode of Extraction - Synthetic and Biological - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 195: Asia-Pacific Historic Review for Ursodeoxycholic Acid by Mode of Extraction - Synthetic and Biological Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 196: Asia-Pacific 15-Year Perspective for Ursodeoxycholic Acid by Mode of Extraction - Percentage Breakdown of Value Sales for Synthetic and Biological for the Years 2015, 2025 & 2030
  • TABLE 197: Asia-Pacific Recent Past, Current & Future Analysis for Ursodeoxycholic Acid by Application - Gastrointestinal Disorders, Liver Disorders, Cystic Fibrosis and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 198: Asia-Pacific Historic Review for Ursodeoxycholic Acid by Application - Gastrointestinal Disorders, Liver Disorders, Cystic Fibrosis and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 199: Asia-Pacific 15-Year Perspective for Ursodeoxycholic Acid by Application - Percentage Breakdown of Value Sales for Gastrointestinal Disorders, Liver Disorders, Cystic Fibrosis and Other Applications for the Years 2015, 2025 & 2030
• AUSTRALIA
  • Ursodeoxycholic Acid Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
  • TABLE 200: Australia Recent Past, Current & Future Analysis for Ursodeoxycholic Acid by Dosage Form - Solid Dosage Form and Liquid Dosage Form - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 201: Australia Historic Review for Ursodeoxycholic Acid by Dosage Form - Solid Dosage Form and Liquid Dosage Form Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 202: Australia 15-Year Perspective for Ursodeoxycholic Acid by Dosage Form - Percentage Breakdown of Value Sales for Solid Dosage Form and Liquid Dosage Form for the Years 2015, 2025 & 2030
  • TABLE 203: Australia Recent Past, Current & Future Analysis for Ursodeoxycholic Acid by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 204: Australia Historic Review for Ursodeoxycholic Acid by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 205: Australia 15-Year Perspective for Ursodeoxycholic Acid by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 206: Australia Recent Past, Current & Future Analysis for Ursodeoxycholic Acid by Mode of Extraction - Synthetic and Biological - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 207: Australia Historic Review for Ursodeoxycholic Acid by Mode of Extraction - Synthetic and Biological Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 208: Australia 15-Year Perspective for Ursodeoxycholic Acid by Mode of Extraction - Percentage Breakdown of Value Sales for Synthetic and Biological for the Years 2015, 2025 & 2030
  • TABLE 209: Australia Recent Past, Current & Future Analysis for Ursodeoxycholic Acid by Application - Gastrointestinal Disorders, Liver Disorders, Cystic Fibrosis and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 210: Australia Historic Review for Ursodeoxycholic Acid by Application - Gastrointestinal Disorders, Liver Disorders, Cystic Fibrosis and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 211: Australia 15-Year Perspective for Ursodeoxycholic Acid by Application - Percentage Breakdown of Value Sales for Gastrointestinal Disorders, Liver Disorders, Cystic Fibrosis and Other Applications for the Years 2015, 2025 & 2030
• INDIA
  • Ursodeoxycholic Acid Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
  • TABLE 212: India Recent Past, Current & Future Analysis for Ursodeoxycholic Acid by Dosage Form - Solid Dosage Form and Liquid Dosage Form - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 213: India Historic Review for Ursodeoxycholic Acid by Dosage Form - Solid Dosage Form and Liquid Dosage Form Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 214: India 15-Year Perspective for Ursodeoxycholic Acid by Dosage Form - Percentage Breakdown of Value Sales for Solid Dosage Form and Liquid Dosage Form for the Years 2015, 2025 & 2030
  • TABLE 215: India Recent Past, Current & Future Analysis for Ursodeoxycholic Acid by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 216: India Historic Review for Ursodeoxycholic Acid by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 217: India 15-Year Perspective for Ursodeoxycholic Acid by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 218: India Recent Past, Current & Future Analysis for Ursodeoxycholic Acid by Mode of Extraction - Synthetic and Biological - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 219: India Historic Review for Ursodeoxycholic Acid by Mode of Extraction - Synthetic and Biological Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 220: India 15-Year Perspective for Ursodeoxycholic Acid by Mode of Extraction - Percentage Breakdown of Value Sales for Synthetic and Biological for the Years 2015, 2025 & 2030
  • TABLE 221: India Recent Past, Current & Future Analysis for Ursodeoxycholic Acid by Application - Gastrointestinal Disorders, Liver Disorders, Cystic Fibrosis and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 222: India Historic Review for Ursodeoxycholic Acid by Application - Gastrointestinal Disorders, Liver Disorders, Cystic Fibrosis and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 223: India 15-Year Perspective for Ursodeoxycholic Acid by Application - Percentage Breakdown of Value Sales for Gastrointestinal Disorders, Liver Disorders, Cystic Fibrosis and Other Applications for the Years 2015, 2025 & 2030
• SOUTH KOREA
  • TABLE 224: South Korea Recent Past, Current & Future Analysis for Ursodeoxycholic Acid by Dosage Form - Solid Dosage Form and Liquid Dosage Form - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 225: South Korea Historic Review for Ursodeoxycholic Acid by Dosage Form - Solid Dosage Form and Liquid Dosage Form Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 226: South Korea 15-Year Perspective for Ursodeoxycholic Acid by Dosage Form - Percentage Breakdown of Value Sales for Solid Dosage Form and Liquid Dosage Form for the Years 2015, 2025 & 2030
  • TABLE 227: South Korea Recent Past, Current & Future Analysis for Ursodeoxycholic Acid by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 228: South Korea Historic Review for Ursodeoxycholic Acid by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 229: South Korea 15-Year Perspective for Ursodeoxycholic Acid by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 230: South Korea Recent Past, Current & Future Analysis for Ursodeoxycholic Acid by Mode of Extraction - Synthetic and Biological - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 231: South Korea Historic Review for Ursodeoxycholic Acid by Mode of Extraction - Synthetic and Biological Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 232: South Korea 15-Year Perspective for Ursodeoxycholic Acid by Mode of Extraction - Percentage Breakdown of Value Sales for Synthetic and Biological for the Years 2015, 2025 & 2030
  • TABLE 233: South Korea Recent Past, Current & Future Analysis for Ursodeoxycholic Acid by Application - Gastrointestinal Disorders, Liver Disorders, Cystic Fibrosis and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 234: South Korea Historic Review for Ursodeoxycholic Acid by Application - Gastrointestinal Disorders, Liver Disorders, Cystic Fibrosis and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 235: South Korea 15-Year Perspective for Ursodeoxycholic Acid by Application - Percentage Breakdown of Value Sales for Gastrointestinal Disorders, Liver Disorders, Cystic Fibrosis and Other Applications for the Years 2015, 2025 & 2030
• REST OF ASIA-PACIFIC
  • TABLE 236: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Ursodeoxycholic Acid by Dosage Form - Solid Dosage Form and Liquid Dosage Form - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 237: Rest of Asia-Pacific Historic Review for Ursodeoxycholic Acid by Dosage Form - Solid Dosage Form and Liquid Dosage Form Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 238: Rest of Asia-Pacific 15-Year Perspective for Ursodeoxycholic Acid by Dosage Form - Percentage Breakdown of Value Sales for Solid Dosage Form and Liquid Dosage Form for the Years 2015, 2025 & 2030
  • TABLE 239: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Ursodeoxycholic Acid by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 240: Rest of Asia-Pacific Historic Review for Ursodeoxycholic Acid by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 241: Rest of Asia-Pacific 15-Year Perspective for Ursodeoxycholic Acid by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 242: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Ursodeoxycholic Acid by Mode of Extraction - Synthetic and Biological - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 243: Rest of Asia-Pacific Historic Review for Ursodeoxycholic Acid by Mode of Extraction - Synthetic and Biological Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 244: Rest of Asia-Pacific 15-Year Perspective for Ursodeoxycholic Acid by Mode of Extraction - Percentage Breakdown of Value Sales for Synthetic and Biological for the Years 2015, 2025 & 2030
  • TABLE 245: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Ursodeoxycholic Acid by Application - Gastrointestinal Disorders, Liver Disorders, Cystic Fibrosis and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 246: Rest of Asia-Pacific Historic Review for Ursodeoxycholic Acid by Application - Gastrointestinal Disorders, Liver Disorders, Cystic Fibrosis and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 247: Rest of Asia-Pacific 15-Year Perspective for Ursodeoxycholic Acid by Application - Percentage Breakdown of Value Sales for Gastrointestinal Disorders, Liver Disorders, Cystic Fibrosis and Other Applications for the Years 2015, 2025 & 2030
• LATIN AMERICA
  • Ursodeoxycholic Acid Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
  • TABLE 248: Latin America Recent Past, Current & Future Analysis for Ursodeoxycholic Acid by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 249: Latin America Historic Review for Ursodeoxycholic Acid by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 250: Latin America 15-Year Perspective for Ursodeoxycholic Acid by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
  • TABLE 251: Latin America Recent Past, Current & Future Analysis for Ursodeoxycholic Acid by Dosage Form - Solid Dosage Form and Liquid Dosage Form - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 252: Latin America Historic Review for Ursodeoxycholic Acid by Dosage Form - Solid Dosage Form and Liquid Dosage Form Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 253: Latin America 15-Year Perspective for Ursodeoxycholic Acid by Dosage Form - Percentage Breakdown of Value Sales for Solid Dosage Form and Liquid Dosage Form for the Years 2015, 2025 & 2030
  • TABLE 254: Latin America Recent Past, Current & Future Analysis for Ursodeoxycholic Acid by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 255: Latin America Historic Review for Ursodeoxycholic Acid by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 256: Latin America 15-Year Perspective for Ursodeoxycholic Acid by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 257: Latin America Recent Past, Current & Future Analysis for Ursodeoxycholic Acid by Mode of Extraction - Synthetic and Biological - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 258: Latin America Historic Review for Ursodeoxycholic Acid by Mode of Extraction - Synthetic and Biological Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 259: Latin America 15-Year Perspective for Ursodeoxycholic Acid by Mode of Extraction - Percentage Breakdown of Value Sales for Synthetic and Biological for the Years 2015, 2025 & 2030
  • TABLE 260: Latin America Recent Past, Current & Future Analysis for Ursodeoxycholic Acid by Application - Gastrointestinal Disorders, Liver Disorders, Cystic Fibrosis and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 261: Latin America Historic Review for Ursodeoxycholic Acid by Application - Gastrointestinal Disorders, Liver Disorders, Cystic Fibrosis and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 262: Latin America 15-Year Perspective for Ursodeoxycholic Acid by Application - Percentage Breakdown of Value Sales for Gastrointestinal Disorders, Liver Disorders, Cystic Fibrosis and Other Applications for the Years 2015, 2025 & 2030
• ARGENTINA
  • TABLE 263: Argentina Recent Past, Current & Future Analysis for Ursodeoxycholic Acid by Dosage Form - Solid Dosage Form and Liquid Dosage Form - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 264: Argentina Historic Review for Ursodeoxycholic Acid by Dosage Form - Solid Dosage Form and Liquid Dosage Form Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 265: Argentina 15-Year Perspective for Ursodeoxycholic Acid by Dosage Form - Percentage Breakdown of Value Sales for Solid Dosage Form and Liquid Dosage Form for the Years 2015, 2025 & 2030
  • TABLE 266: Argentina Recent Past, Current & Future Analysis for Ursodeoxycholic Acid by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 267: Argentina Historic Review for Ursodeoxycholic Acid by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 268: Argentina 15-Year Perspective for Ursodeoxycholic Acid by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 269: Argentina Recent Past, Current & Future Analysis for Ursodeoxycholic Acid by Mode of Extraction - Synthetic and Biological - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 270: Argentina Historic Review for Ursodeoxycholic Acid by Mode of Extraction - Synthetic and Biological Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 271: Argentina 15-Year Perspective for Ursodeoxycholic Acid by Mode of Extraction - Percentage Breakdown of Value Sales for Synthetic and Biological for the Years 2015, 2025 & 2030
  • TABLE 272: Argentina Recent Past, Current & Future Analysis for Ursodeoxycholic Acid by Application - Gastrointestinal Disorders, Liver Disorders, Cystic Fibrosis and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 273: Argentina Historic Review for Ursodeoxycholic Acid by Application - Gastrointestinal Disorders, Liver Disorders, Cystic Fibrosis and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 274: Argentina 15-Year Perspective for Ursodeoxycholic Acid by Application - Percentage Breakdown of Value Sales for Gastrointestinal Disorders, Liver Disorders, Cystic Fibrosis and Other Applications for the Years 2015, 2025 & 2030
• BRAZIL
  • TABLE 275: Brazil Recent Past, Current & Future Analysis for Ursodeoxycholic Acid by Dosage Form - Solid Dosage Form and Liquid Dosage Form - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 276: Brazil Historic Review for Ursodeoxycholic Acid by Dosage Form - Solid Dosage Form and Liquid Dosage Form Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 277: Brazil 15-Year Perspective for Ursodeoxycholic Acid by Dosage Form - Percentage Breakdown of Value Sales for Solid Dosage Form and Liquid Dosage Form for the Years 2015, 2025 & 2030
  • TABLE 278: Brazil Recent Past, Current & Future Analysis for Ursodeoxycholic Acid by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 279: Brazil Historic Review for Ursodeoxycholic Acid by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 280: Brazil 15-Year Perspective for Ursodeoxycholic Acid by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 281: Brazil Recent Past, Current & Future Analysis for Ursodeoxycholic Acid by Mode of Extraction - Synthetic and Biological - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 282: Brazil Historic Review for Ursodeoxycholic Acid by Mode of Extraction - Synthetic and Biological Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 283: Brazil 15-Year Perspective for Ursodeoxycholic Acid by Mode of Extraction - Percentage Breakdown of Value Sales for Synthetic and Biological for the Years 2015, 2025 & 2030
  • TABLE 284: Brazil Recent Past, Current & Future Analysis for Ursodeoxycholic Acid by Application - Gastrointestinal Disorders, Liver Disorders, Cystic Fibrosis and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 285: Brazil Historic Review for Ursodeoxycholic Acid by Application - Gastrointestinal Disorders, Liver Disorders, Cystic Fibrosis and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 286: Brazil 15-Year Perspective for Ursodeoxycholic Acid by Application - Percentage Breakdown of Value Sales for Gastrointestinal Disorders, Liver Disorders, Cystic Fibrosis and Other Applications for the Years 2015, 2025 & 2030
• MEXICO
  • TABLE 287: Mexico Recent Past, Current & Future Analysis for Ursodeoxycholic Acid by Dosage Form - Solid Dosage Form and Liquid Dosage Form - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 288: Mexico Historic Review for Ursodeoxycholic Acid by Dosage Form - Solid Dosage Form and Liquid Dosage Form Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 289: Mexico 15-Year Perspective for Ursodeoxycholic Acid by Dosage Form - Percentage Breakdown of Value Sales for Solid Dosage Form and Liquid Dosage Form for the Years 2015, 2025 & 2030
  • TABLE 290: Mexico Recent Past, Current & Future Analysis for Ursodeoxycholic Acid by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 291: Mexico Historic Review for Ursodeoxycholic Acid by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 292: Mexico 15-Year Perspective for Ursodeoxycholic Acid by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 293: Mexico Recent Past, Current & Future Analysis for Ursodeoxycholic Acid by Mode of Extraction - Synthetic and Biological - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 294: Mexico Historic Review for Ursodeoxycholic Acid by Mode of Extraction - Synthetic and Biological Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 295: Mexico 15-Year Perspective for Ursodeoxycholic Acid by Mode of Extraction - Percentage Breakdown of Value Sales for Synthetic and Biological for the Years 2015, 2025 & 2030
  • TABLE 296: Mexico Recent Past, Current & Future Analysis for Ursodeoxycholic Acid by Application - Gastrointestinal Disorders, Liver Disorders, Cystic Fibrosis and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 297: Mexico Historic Review for Ursodeoxycholic Acid by Application - Gastrointestinal Disorders, Liver Disorders, Cystic Fibrosis and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 298: Mexico 15-Year Perspective for Ursodeoxycholic Acid by Application - Percentage Breakdown of Value Sales for Gastrointestinal Disorders, Liver Disorders, Cystic Fibrosis and Other Applications for the Years 2015, 2025 & 2030
• REST OF LATIN AMERICA
  • TABLE 299: Rest of Latin America Recent Past, Current & Future Analysis for Ursodeoxycholic Acid by Dosage Form - Solid Dosage Form and Liquid Dosage Form - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 300: Rest of Latin America Historic Review for Ursodeoxycholic Acid by Dosage Form - Solid Dosage Form and Liquid Dosage Form Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 301: Rest of Latin America 15-Year Perspective for Ursodeoxycholic Acid by Dosage Form - Percentage Breakdown of Value Sales for Solid Dosage Form and Liquid Dosage Form for the Years 2015, 2025 & 2030
  • TABLE 302: Rest of Latin America Recent Past, Current & Future Analysis for Ursodeoxycholic Acid by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 303: Rest of Latin America Historic Review for Ursodeoxycholic Acid by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 304: Rest of Latin America 15-Year Perspective for Ursodeoxycholic Acid by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 305: Rest of Latin America Recent Past, Current & Future Analysis for Ursodeoxycholic Acid by Mode of Extraction - Synthetic and Biological - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 306: Rest of Latin America Historic Review for Ursodeoxycholic Acid by Mode of Extraction - Synthetic and Biological Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 307: Rest of Latin America 15-Year Perspective for Ursodeoxycholic Acid by Mode of Extraction - Percentage Breakdown of Value Sales for Synthetic and Biological for the Years 2015, 2025 & 2030
  • TABLE 308: Rest of Latin America Recent Past, Current & Future Analysis for Ursodeoxycholic Acid by Application - Gastrointestinal Disorders, Liver Disorders, Cystic Fibrosis and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 309: Rest of Latin America Historic Review for Ursodeoxycholic Acid by Application - Gastrointestinal Disorders, Liver Disorders, Cystic Fibrosis and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 310: Rest of Latin America 15-Year Perspective for Ursodeoxycholic Acid by Application - Percentage Breakdown of Value Sales for Gastrointestinal Disorders, Liver Disorders, Cystic Fibrosis and Other Applications for the Years 2015, 2025 & 2030
• MIDDLE EAST
  • Ursodeoxycholic Acid Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
  • TABLE 311: Middle East Recent Past, Current & Future Analysis for Ursodeoxycholic Acid by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 312: Middle East Historic Review for Ursodeoxycholic Acid by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 313: Middle East 15-Year Perspective for Ursodeoxycholic Acid by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
  • TABLE 314: Middle East Recent Past, Current & Future Analysis for Ursodeoxycholic Acid by Dosage Form - Solid Dosage Form and Liquid Dosage Form - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 315: Middle East Historic Review for Ursodeoxycholic Acid by Dosage Form - Solid Dosage Form and Liquid Dosage Form Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 316: Middle East 15-Year Perspective for Ursodeoxycholic Acid by Dosage Form - Percentage Breakdown of Value Sales for Solid Dosage Form and Liquid Dosage Form for the Years 2015, 2025 & 2030
  • TABLE 317: Middle East Recent Past, Current & Future Analysis for Ursodeoxycholic Acid by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 318: Middle East Historic Review for Ursodeoxycholic Acid by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 319: Middle East 15-Year Perspective for Ursodeoxycholic Acid by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 320: Middle East Recent Past, Current & Future Analysis for Ursodeoxycholic Acid by Mode of Extraction - Synthetic and Biological - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 321: Middle East Historic Review for Ursodeoxycholic Acid by Mode of Extraction - Synthetic and Biological Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 322: Middle East 15-Year Perspective for Ursodeoxycholic Acid by Mode of Extraction - Percentage Breakdown of Value Sales for Synthetic and Biological for the Years 2015, 2025 & 2030
  • TABLE 323: Middle East Recent Past, Current & Future Analysis for Ursodeoxycholic Acid by Application - Gastrointestinal Disorders, Liver Disorders, Cystic Fibrosis and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 324: Middle East Historic Review for Ursodeoxycholic Acid by Application - Gastrointestinal Disorders, Liver Disorders, Cystic Fibrosis and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 325: Middle East 15-Year Perspective for Ursodeoxycholic Acid by Application - Percentage Breakdown of Value Sales for Gastrointestinal Disorders, Liver Disorders, Cystic Fibrosis and Other Applications for the Years 2015, 2025 & 2030
• IRAN
  • TABLE 326: Iran Recent Past, Current & Future Analysis for Ursodeoxycholic Acid by Dosage Form - Solid Dosage Form and Liquid Dosage Form - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 327: Iran Historic Review for Ursodeoxycholic Acid by Dosage Form - Solid Dosage Form and Liquid Dosage Form Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 328: Iran 15-Year Perspective for Ursodeoxycholic Acid by Dosage Form - Percentage Breakdown of Value Sales for Solid Dosage Form and Liquid Dosage Form for the Years 2015, 2025 & 2030
  • TABLE 329: Iran Recent Past, Current & Future Analysis for Ursodeoxycholic Acid by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 330: Iran Historic Review for Ursodeoxycholic Acid by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 331: Iran 15-Year Perspective for Ursodeoxycholic Acid by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 332: Iran Recent Past, Current & Future Analysis for Ursodeoxycholic Acid by Mode of Extraction - Synthetic and Biological - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 333: Iran Historic Review for Ursodeoxycholic Acid by Mode of Extraction - Synthetic and Biological Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 334: Iran 15-Year Perspective for Ursodeoxycholic Acid by Mode of Extraction - Percentage Breakdown of Value Sales for Synthetic and Biological for the Years 2015, 2025 & 2030
  • TABLE 335: Iran Recent Past, Current & Future Analysis for Ursodeoxycholic Acid by Application - Gastrointestinal Disorders, Liver Disorders, Cystic Fibrosis and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 336: Iran Historic Review for Ursodeoxycholic Acid by Application - Gastrointestinal Disorders, Liver Disorders, Cystic Fibrosis and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 337: Iran 15-Year Perspective for Ursodeoxycholic Acid by Application - Percentage Breakdown of Value Sales for Gastrointestinal Disorders, Liver Disorders, Cystic Fibrosis and Other Applications for the Years 2015, 2025 & 2030
• ISRAEL
  • TABLE 338: Israel Recent Past, Current & Future Analysis for Ursodeoxycholic Acid by Dosage Form - Solid Dosage Form and Liquid Dosage Form - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 339: Israel Historic Review for Ursodeoxycholic Acid by Dosage Form - Solid Dosage Form and Liquid Dosage Form Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 340: Israel 15-Year Perspective for Ursodeoxycholic Acid by Dosage Form - Percentage Breakdown of Value Sales for Solid Dosage Form and Liquid Dosage Form for the Years 2015, 2025 & 2030
  • TABLE 341: Israel Recent Past, Current & Future Analysis for Ursodeoxycholic Acid by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 342: Israel Historic Review for Ursodeoxycholic Acid by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 343: Israel 15-Year Perspective for Ursodeoxycholic Acid by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 344: Israel Recent Past, Current & Future Analysis for Ursodeoxycholic Acid by Mode of Extraction - Synthetic and Biological - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 345: Israel Historic Review for Ursodeoxycholic Acid by Mode of Extraction - Synthetic and Biological Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 346: Israel 15-Year Perspective for Ursodeoxycholic Acid by Mode of Extraction - Percentage Breakdown of Value Sales for Synthetic and Biological for the Years 2015, 2025 & 2030
  • TABLE 347: Israel Recent Past, Current & Future Analysis for Ursodeoxycholic Acid by Application - Gastrointestinal Disorders, Liver Disorders, Cystic Fibrosis and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 348: Israel Historic Review for Ursodeoxycholic Acid by Application - Gastrointestinal Disorders, Liver Disorders, Cystic Fibrosis and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 349: Israel 15-Year Perspective for Ursodeoxycholic Acid by Application - Percentage Breakdown of Value Sales for Gastrointestinal Disorders, Liver Disorders, Cystic Fibrosis and Other Applications for the Years 2015, 2025 & 2030
• SAUDI ARABIA
  • TABLE 350: Saudi Arabia Recent Past, Current & Future Analysis for Ursodeoxycholic Acid by Dosage Form - Solid Dosage Form and Liquid Dosage Form - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 351: Saudi Arabia Historic Review for Ursodeoxycholic Acid by Dosage Form - Solid Dosage Form and Liquid Dosage Form Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 352: Saudi Arabia 15-Year Perspective for Ursodeoxycholic Acid by Dosage Form - Percentage Breakdown of Value Sales for Solid Dosage Form and Liquid Dosage Form for the Years 2015, 2025 & 2030
  • TABLE 353: Saudi Arabia Recent Past, Current & Future Analysis for Ursodeoxycholic Acid by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 354: Saudi Arabia Historic Review for Ursodeoxycholic Acid by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 355: Saudi Arabia 15-Year Perspective for Ursodeoxycholic Acid by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 356: Saudi Arabia Recent Past, Current & Future Analysis for Ursodeoxycholic Acid by Mode of Extraction - Synthetic and Biological - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 357: Saudi Arabia Historic Review for Ursodeoxycholic Acid by Mode of Extraction - Synthetic and Biological Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 358: Saudi Arabia 15-Year Perspective for Ursodeoxycholic Acid by Mode of Extraction - Percentage Breakdown of Value Sales for Synthetic and Biological for the Years 2015, 2025 & 2030
  • TABLE 359: Saudi Arabia Recent Past, Current & Future Analysis for Ursodeoxycholic Acid by Application - Gastrointestinal Disorders, Liver Disorders, Cystic Fibrosis and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 360: Saudi Arabia Historic Review for Ursodeoxycholic Acid by Application - Gastrointestinal Disorders, Liver Disorders, Cystic Fibrosis and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 361: Saudi Arabia 15-Year Perspective for Ursodeoxycholic Acid by Application - Percentage Breakdown of Value Sales for Gastrointestinal Disorders, Liver Disorders, Cystic Fibrosis and Other Applications for the Years 2015, 2025 & 2030
• UNITED ARAB EMIRATES
  • TABLE 362: UAE Recent Past, Current & Future Analysis for Ursodeoxycholic Acid by Dosage Form - Solid Dosage Form and Liquid Dosage Form - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 363: UAE Historic Review for Ursodeoxycholic Acid by Dosage Form - Solid Dosage Form and Liquid Dosage Form Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 364: UAE 15-Year Perspective for Ursodeoxycholic Acid by Dosage Form - Percentage Breakdown of Value Sales for Solid Dosage Form and Liquid Dosage Form for the Years 2015, 2025 & 2030
  • TABLE 365: UAE Recent Past, Current & Future Analysis for Ursodeoxycholic Acid by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 366: UAE Historic Review for Ursodeoxycholic Acid by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 367: UAE 15-Year Perspective for Ursodeoxycholic Acid by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 368: UAE Recent Past, Current & Future Analysis for Ursodeoxycholic Acid by Mode of Extraction - Synthetic and Biological - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 369: UAE Historic Review for Ursodeoxycholic Acid by Mode of Extraction - Synthetic and Biological Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 370: UAE 15-Year Perspective for Ursodeoxycholic Acid by Mode of Extraction - Percentage Breakdown of Value Sales for Synthetic and Biological for the Years 2015, 2025 & 2030
  • TABLE 371: UAE Recent Past, Current & Future Analysis for Ursodeoxycholic Acid by Application - Gastrointestinal Disorders, Liver Disorders, Cystic Fibrosis and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 372: UAE Historic Review for Ursodeoxycholic Acid by Application - Gastrointestinal Disorders, Liver Disorders, Cystic Fibrosis and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 373: UAE 15-Year Perspective for Ursodeoxycholic Acid by Application - Percentage Breakdown of Value Sales for Gastrointestinal Disorders, Liver Disorders, Cystic Fibrosis and Other Applications for the Years 2015, 2025 & 2030
• REST OF MIDDLE EAST
  • TABLE 374: Rest of Middle East Recent Past, Current & Future Analysis for Ursodeoxycholic Acid by Dosage Form - Solid Dosage Form and Liquid Dosage Form - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 375: Rest of Middle East Historic Review for Ursodeoxycholic Acid by Dosage Form - Solid Dosage Form and Liquid Dosage Form Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 376: Rest of Middle East 15-Year Perspective for Ursodeoxycholic Acid by Dosage Form - Percentage Breakdown of Value Sales for Solid Dosage Form and Liquid Dosage Form for the Years 2015, 2025 & 2030
  • TABLE 377: Rest of Middle East Recent Past, Current & Future Analysis for Ursodeoxycholic Acid by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 378: Rest of Middle East Historic Review for Ursodeoxycholic Acid by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 379: Rest of Middle East 15-Year Perspective for Ursodeoxycholic Acid by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 380: Rest of Middle East Recent Past, Current & Future Analysis for Ursodeoxycholic Acid by Mode of Extraction - Synthetic and Biological - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 381: Rest of Middle East Historic Review for Ursodeoxycholic Acid by Mode of Extraction - Synthetic and Biological Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 382: Rest of Middle East 15-Year Perspective for Ursodeoxycholic Acid by Mode of Extraction - Percentage Breakdown of Value Sales for Synthetic and Biological for the Years 2015, 2025 & 2030
  • TABLE 383: Rest of Middle East Recent Past, Current & Future Analysis for Ursodeoxycholic Acid by Application - Gastrointestinal Disorders, Liver Disorders, Cystic Fibrosis and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 384: Rest of Middle East Historic Review for Ursodeoxycholic Acid by Application - Gastrointestinal Disorders, Liver Disorders, Cystic Fibrosis and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 385: Rest of Middle East 15-Year Perspective for Ursodeoxycholic Acid by Application - Percentage Breakdown of Value Sales for Gastrointestinal Disorders, Liver Disorders, Cystic Fibrosis and Other Applications for the Years 2015, 2025 & 2030
• AFRICA
  • Ursodeoxycholic Acid Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
  • TABLE 386: Africa Recent Past, Current & Future Analysis for Ursodeoxycholic Acid by Dosage Form - Solid Dosage Form and Liquid Dosage Form - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 387: Africa Historic Review for Ursodeoxycholic Acid by Dosage Form - Solid Dosage Form and Liquid Dosage Form Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 388: Africa 15-Year Perspective for Ursodeoxycholic Acid by Dosage Form - Percentage Breakdown of Value Sales for Solid Dosage Form and Liquid Dosage Form for the Years 2015, 2025 & 2030
  • TABLE 389: Africa Recent Past, Current & Future Analysis for Ursodeoxycholic Acid by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 390: Africa Historic Review for Ursodeoxycholic Acid by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 391: Africa 15-Year Perspective for Ursodeoxycholic Acid by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 392: Africa Recent Past, Current & Future Analysis for Ursodeoxycholic Acid by Mode of Extraction - Synthetic and Biological - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 393: Africa Historic Review for Ursodeoxycholic Acid by Mode of Extraction - Synthetic and Biological Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 394: Africa 15-Year Perspective for Ursodeoxycholic Acid by Mode of Extraction - Percentage Breakdown of Value Sales for Synthetic and Biological for the Years 2015, 2025 & 2030
  • TABLE 395: Africa Recent Past, Current & Future Analysis for Ursodeoxycholic Acid by Application - Gastrointestinal Disorders, Liver Disorders, Cystic Fibrosis and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 396: Africa Historic Review for Ursodeoxycholic Acid by Application - Gastrointestinal Disorders, Liver Disorders, Cystic Fibrosis and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 397: Africa 15-Year Perspective for Ursodeoxycholic Acid by Application - Percentage Breakdown of Value Sales for Gastrointestinal Disorders, Liver Disorders, Cystic Fibrosis and Other Applications for the Years 2015, 2025 & 2030

IV. COMPETITION